Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2022

View Archived Issues

Humanwell Healthcare discloses LPAR1 antagonists

CURACLE and collaborators patent carbazole derivative angiogenesis inhibitors

French researchers patent gold complexes and their use as antioxidants

ATP spreads inflammation by activating neural pathway and enhancing IL-6 amplifier

Ningbo Combireg Pharmaceutical Technology presents deuterated anticancer compounds

Platelet-activating factor receptor antagonists discovered at Boehringer Ingelheim

Novel polyphenol derivative as potent DYRK1A inhibitor for the treatment of MS

Cilagicin, next-generation antibiotic with activity against MDR isolates

High-throughput proteomics identifies biomarkers of both rheumatoid arthritis and SLE

FDA clears Passage Bio's IND for PBML-04 for metachromatic leukodystrophy

Qualigen Therapeutics initiates IND-enabling studies for QN-302

OnCusp licenses ex-China rights to Multitude's CDH6 antibody-drug conjugate

China's NMPA approves IND for B7H4x4-1BB bispecific antibody HBM-7008

MetasTx advances MTX-101 for prostate cancer and metastasis prevention

FDA clears IND application for SBT-115301 for autoimmune disease

For mutations, "synonymous" is not a synonym for silent, study finds

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...